Active ingredients: nizatidine
What it is used for
TAZAC is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. TAZAC is also indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of active duodenal ulcer. Continuous therapy with nizatidine for longer than 1 year has not been studied. TAZAC is indicated for up to 8 weeks for the treatment of benign gastric ulcer. TAZAC is indicated for up to 12 weeks for the treatment of oesophagitis, including erosive and ulcerative oesophagitis and associated heartburn due to reflux.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 25 degrees Celsius
- Lifetime is 3 Years.
Always read the label. If symptoms persist see your healthcare professional.
Size 2 capsule consisting of dark yellow cap and a pale yellow body, printed with "N150" on body.
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
Is this medicine subsidised?
This medicine is subsidised which may make it cheaper. To learn more about this subsidy, visit the Phamaceutical Benefits Scheme (PBS) website
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy?
For the active ingredient nizatidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)